<DOC>
	<DOCNO>NCT02851056</DOCNO>
	<brief_summary>The purpose study test effect ( good bad ) new cancer vaccine participant cancer , administer autologous hematopoietic cell transplant ( HCT ) . The name vaccine call Dendritic Cell Survivin Vaccine ( DC : AdmS ) . The vaccine make use participant 's blood cell . The vaccine contain virus call adenovirus , similar virus cause common cold . The virus change infect human cause infection . The vaccine prepared Moffitt Cancer Center Cell Therapy Laboratory Facility .</brief_summary>
	<brief_title>Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant ( HCT )</brief_title>
	<detailed_description>This pilot study design test safety biological activity survivin vaccine . A sample size 10 patient establish feasibility approach , allow evaluation expect increase T cell response survivin . Vaccine administer two stage . After first survivin vaccination , patient mobilize granulocyte-colony stimulating factor ( G-CSF ) vivo-primed T cell stem cell collect apheresis ( graft ) . T cell Cluster Differentiation 34 ( CD34 ) progenitor cell transfer back patient time autologous graft infusion . Patients receive re-vaccination , near , day 21 transplant . We assess immune response survivin 6 month compare pre-vaccine response . To validate patient 's ability mount immune response simultaneous vaccinate Prevnar13Â® , pneumococcus vaccine able elicit T cell immune response . Immunologic responses measure baseline , stem cell mobilization/collection , 60 day , 90 day , 180 day transplant . Peripheral blood mononuclear cell ( PBMCs ) isolate stored liquid N2 . G-CSF cell mobilization , mononuclear cell collection , melphalan chemotherapy , transplant infusion per institution standard .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Screening : As protocol Version 2 `` screening phase '' .Patients previously consent screening phase could still eligible treatment consent treatment , base upon updated eligibility criterion . Treatment : Patients histologically confirm Multiple Myeloma consider high dose chemotherapy autologous stem cell transplant . Patients must bone marrow biopsy available , one schedule perform clinical indication survivin expression could determine ( note : survivin stain tumor need result prior enrollment treatment obtain correlative science ) . Patients plan treatment high dose melphalan autologous hematopoietic cell transplant ( HCT ) . Complete blood count ( CBC ) absolute neutrophil count ( ANC ) &gt; = 1,000/uL , hemoglobin &gt; = 8.0 g/dL platelet count &gt; = 50,000/uL . Liver enzymes : total bilirubin less equal 2 mg/dL ( &gt; 2 mg/dL permit patient evidence Gilbert 's disease base upon prior bilirubin elevation genetic testing ) ; Aspartate Aminotransferase ( AST ) Alanine Aminotransferase ( ALT ) less 1.5 X upper limit normal ( ULN ) . Signed informed consent form accordance institutional federal law policy . Treatment : Patients Complete Response ( CR ) stringent CR induction therapy define International Response Criteria recent therapy . Patients progressive disease time transplant . Pregnant lactate woman ( evaluate serum test within 48 hour administration first vaccine woman child bear potential ) . HIV infection confirm nucleic acid test ( NAT ) . Common variable immunodeficiency . Active central nervous system ( CNS ) malignancy . Active bacterial , fungal viral infection . Prior history allogeneic hematopoietic cell transplantation Prior malignancy within 5 year enrollment exclude nonmelanoma skin cancer cervical carcinoma curative resection , require chemotherapy . History severe allergy ( e.g. , anaphylaxis ) component Prevnar diphtheriatoxoid contain vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Dendritic cell</keyword>
	<keyword>autologous hematopoietic cell transplant</keyword>
	<keyword>HCT</keyword>
</DOC>